Research Reports

Key takeaways

Entered Stock Exchange Agreement on March 26, 2026, with CEO Lourdes Felix, President Louis C Lucido, and Director Kent Emry.

Shareholders transferred 1,215 Subsidiary shares (12.15% ownership) for 2,263,371 restricted Parent Shares.

Exchange closed March 27, 2026, as part of Plan of Reorganization approved February 25, 2026.

Intended as tax-free reorganization under Section 368(a)(1)(B); no cash or other property involved.

Parent Shares issued under Section 4(a)(2) exemption; Shareholders receive registration rights.

Board approved transaction per related party transaction policy.

Full analysis

The stock exchange enables BioCorRx Inc. to increase control over its majority-owned subsidiary BioCorRx Pharmaceuticals, Inc., aligning with the company's Plan of Reorganization to meet Section 368(c) control requirements for a tax-free restructuring. Insiders, including the CEO, President, and a director, contributed their minority stakes representing 12.15% of the subsidiary's common stock, receiving restricted Parent Shares in return. This related-party transaction, pre-approved by the Board under the company's policy, avoids cash outlay and preserves liquidity while providing shareholders with equity upside and limited registration rights. The unregistered issuance relies on private placement exemptions, with Parent Shares bearing resale restrictions under Rule 144, reflecting the non-public nature of the deal among accredited insiders familiar with the company.

BICX · BioCorRx Inc.

Summary

Key takeaways

Full analysis